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Introduction: The  effect  of  pharmacological  agents  on  recovery  in  chronic  disorders  of 
consciousness remains unsatisfactory. Amantadine, a dopaminergic agonist, has been suggested 
to behaviorally improve recovery from vegetative (VS) and minimally conscious states (MCS). 
Here, we report the effect of amantadine in a chronic anoxic MCS patient (i.e., presence of visual 
pursuit). 
Methods: An ABAB design was proposed in conjunction with weekly CRS-R (Coma Recovery 
Scale-Revised)  assessment,  actimetry  monitoring  and  serial  (18F)fluorodeoxyglucose-PET (3 
weeks baseline period, amantadine administrated during 6 weeks, stopped during 6 weeks and 
again resumed for 6 weeks). 
Results: After  3  weeks  of  amantadine  treatment,  the  patient  showed reproducible  movement  to 
command and consistent automatic motor responses permitting mouth feeding. Similarly, actimetry  
monitoring showed a significant increase in limb movements during treatment periods. Finally, serial  
FDG-PET  scanning  objectively  measured  treatment-related  metabolic  changes  in  a  widespread 
fronto-temporo-parietal network and in the sensori-motor area. 
Conclusion: These  data  suggest  a  modulation  of  polymodal  associative  cortical  metabolism and 
motor function by amantadine. Large scale studies on the efficiency of amantadine in this challenging  
patient population are warranted.
